Idorsia
Dr. Carl-Heinz Grimm serves as the VP and Head of Analytical Development & Quality Control at Idorsia Pharmaceuticals Ltd since January 2023, contributing to the Global Pharmaceutical Development Leadership Team and overseeing a diverse team in various analytical disciplines. With extensive experience at Boehringer Ingelheim from 2005 to 2022, Dr. Grimm held multiple leadership roles, including Head of CoC Real Time Release and Head of Quality Control Services, where responsibilities spanned global quality functions, digitalization initiatives, and project management for biopharmaceutical products. Dr. Grimm's career commenced with a post-doc role at Abbott, emphasizing immunological analytical processes, and academic achievements include a Ph.D. in Pharmacy from Ludwig-Maximilians-Universität München and leadership training at St. Gallen Business School and Duke University.
This person is not in any teams
This person is not in any offices
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.